December 07, 2006
Gilead Sciences Receives Subpoena from U.S. Department of Justice
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 7, 2006--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that it has received a subpoena from the United States Attorney's Office in San Francisco requesting documents regarding its marketing and medical education programs for Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), Viread(R) (tenofovir disoproxil fumarate) and Emtriva(R) (emtricitabine). Gilead intends to comply with the U.S. Attorney's subpoena and to cooperate in any related government investigation.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.